Immunotech Laboratories, Inc. Updates Progress on Negotiations for Phase III Testing on its Treatments for HIV/AIDS & Hepatit...
October 07 2014 - 9:00AM
Business Wire
Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) and Immunotech
Laboratories, BG. recently announced the successful completion of
Phase I and Phase II field trials in Bulgaria of the Company’s
HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) and
have begun negotiations for sites in Macedonia and Serbia for Phase
III testing on human patients. The clinical test are being
conducted through Immunotech Laboratories, BG (“IMMB-BG”) Since
2013 IMMB-BG hired and funded the Clinical Research Organization
(“CRO”) to conduct all preclinical and monitoring phase III
clinical studies. The product for the Bulgarian study was produce
under GMP conditions by a US. Contract Manufacturing Facility.
The successful completion of Phase III clinical study testing
would enable Immunotech Laboratories (IMMB) to move forward using
the Phase I, II, & III clinical trial results, for the FDA
application pertaining to legal use of the treatment for HIV/AIDS
and Hepatitis “C” patients in the USA.
About Immunotech Laboratories, Inc.
Headquartered in Monrovia, CA, Immunotech Laboratories is a drug
development company committed to the commercialization of its
proprietary proteins for the treatment of debilitating infectious
diseases. The Company strives to become a leader in
immuno-therapeutic treatment and prevention of HIV/AIDS, Cancer and
other immuno related disorders.
For more information visit: http://www.immunotechlab.com.
Safe Harbor Statement: This news release contains
forward-looking statements that involve risks and uncertainties
associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other
risks described by Immunotech Laboratories, Inc. from time to time
in its periodic reports filed with the SEC. IPF is not approved by
the US Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Immunotech Laboratories
believes that the forward-looking statements and underlying
assumptions contained therein are reasonable, any of the
assumptions could be inaccurate, including, but not limited to, the
ability of Immunotech Laboratories to establish the efficacy of IPF
in the treatment of any disease or health condition, the
development of studies and strategies leading to commercialization
of IPF in the United States, the obtaining of funding required to
carry out the development plan, the completion of studies and tests
on time or at all, and the successful outcome of such studies or
tests. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to
be accurate. In light of the significant uncertainties inherent in
the forward-looking statements included herein, Immunotech
Laboratories or any other person that the objectives and plans of
Immunotech Laboratories will be achieved should not regard the
forward-looking statements as a representation.
Contact:
Immunotech Laboratories, Inc.ir@immunotechlab.com
GIC813-213-8156Houston, Texas
Immunotech Laboratories, Inc.GIC813-213-8156Houston, Texas
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Apr 2023 to Apr 2024
